CA2970440A1 - Cell co-expressing chimeric antigen receptors binding cd19 and cd22 - Google Patents
Cell co-expressing chimeric antigen receptors binding cd19 and cd22 Download PDFInfo
- Publication number
- CA2970440A1 CA2970440A1 CA2970440A CA2970440A CA2970440A1 CA 2970440 A1 CA2970440 A1 CA 2970440A1 CA 2970440 A CA2970440 A CA 2970440A CA 2970440 A CA2970440 A CA 2970440A CA 2970440 A1 CA2970440 A1 CA 2970440A1
- Authority
- CA
- Canada
- Prior art keywords
- car
- nucleic acid
- acid sequence
- domain
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 487
- 230000027455 binding Effects 0.000 title claims abstract description 135
- 210000004027 cell Anatomy 0.000 claims abstract description 162
- 239000000427 antigen Substances 0.000 claims abstract description 135
- 102000036639 antigens Human genes 0.000 claims abstract description 134
- 108091007433 antigens Proteins 0.000 claims abstract description 134
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims abstract description 109
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims abstract description 108
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims abstract description 101
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims abstract description 98
- 150000007523 nucleic acids Chemical group 0.000 claims description 188
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 184
- 125000006850 spacer group Chemical group 0.000 claims description 107
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 86
- 239000013598 vector Substances 0.000 claims description 61
- 206010028980 Neoplasm Diseases 0.000 claims description 43
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 22
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 22
- 108020004705 Codon Proteins 0.000 claims description 21
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 21
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 21
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000012528 membrane Substances 0.000 claims description 18
- 230000004068 intracellular signaling Effects 0.000 claims description 16
- 230000004186 co-expression Effects 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 238000003776 cleavage reaction Methods 0.000 claims description 12
- 230000007017 scission Effects 0.000 claims description 12
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 9
- 238000010361 transduction Methods 0.000 claims description 9
- 230000001177 retroviral effect Effects 0.000 claims description 8
- 230000026683 transduction Effects 0.000 claims description 8
- 238000001890 transfection Methods 0.000 claims description 8
- 230000036210 malignancy Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 230000006801 homologous recombination Effects 0.000 claims description 6
- 238000002744 homologous recombination Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002955 isolation Methods 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 description 38
- 229940024606 amino acid Drugs 0.000 description 27
- 239000011230 binding agent Substances 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108010076504 Protein Sorting Signals Proteins 0.000 description 17
- 230000008685 targeting Effects 0.000 description 15
- 241001529936 Murinae Species 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 230000004913 activation Effects 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 210000003289 regulatory T cell Anatomy 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 230000002147 killing effect Effects 0.000 description 9
- 208000032839 leukemia Diseases 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 210000000822 natural killer cell Anatomy 0.000 description 9
- 210000000130 stem cell Anatomy 0.000 description 8
- 238000013461 design Methods 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000022534 cell killing Effects 0.000 description 5
- 210000003071 memory t lymphocyte Anatomy 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 230000002688 persistence Effects 0.000 description 5
- 108700024394 Exon Proteins 0.000 description 4
- 101001070329 Geobacillus stearothermophilus 50S ribosomal protein L18 Proteins 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 210000004180 plasmocyte Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 101150018757 CD19 gene Proteins 0.000 description 3
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000012642 immune effector Substances 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 108091008042 inhibitory receptors Proteins 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000005868 ontogenesis Effects 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 108010087967 type I signal peptidase Proteins 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 201000003791 MALT lymphoma Diseases 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 101100154912 Mus musculus Tyrp1 gene Proteins 0.000 description 2
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 241000442474 Pulsatilla vulgaris Species 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 108010002082 endometriosis protein-1 Proteins 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 102000027596 immune receptors Human genes 0.000 description 2
- 108091008915 immune receptors Proteins 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 210000002602 induced regulatory T cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 108010017312 CCR2 Receptors Proteins 0.000 description 1
- 108010005327 CD19-specific chimeric antigen receptor Proteins 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101001003194 Eleusine coracana Alpha-amylase/trypsin inhibitor Proteins 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101150027879 FOXP3 gene Proteins 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000619708 Homo sapiens Peroxiredoxin-6 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 238000005588 Kraus reaction Methods 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 101100109406 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aga-1 gene Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102100022239 Peroxiredoxin-6 Human genes 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102100040207 Poly(A) polymerase beta Human genes 0.000 description 1
- 101710192595 Polyamine aminopropyltransferase Proteins 0.000 description 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101710138747 Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
- 102000001613 Sialic Acid Binding Ig-like Lectin 2 Human genes 0.000 description 1
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 1
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000011778 T-cell/histiocyte rich large B cell lymphoma Diseases 0.000 description 1
- 241001648840 Thosea asigna virus Species 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 102000044389 human CD22 Human genes 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 210000004964 innate lymphoid cell Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/505—CD4; CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3224507A CA3224507A1 (en) | 2014-12-24 | 2015-12-23 | Cell co-expressing chimeric antigen receptors binding cd19 and cd22 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201423172 | 2014-12-24 | ||
| GB1423172.4 | 2014-12-24 | ||
| PCT/GB2015/054137 WO2016102965A1 (en) | 2014-12-24 | 2015-12-23 | Cell |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3224507A Division CA3224507A1 (en) | 2014-12-24 | 2015-12-23 | Cell co-expressing chimeric antigen receptors binding cd19 and cd22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2970440A1 true CA2970440A1 (en) | 2016-06-30 |
Family
ID=55066668
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2970440A Pending CA2970440A1 (en) | 2014-12-24 | 2015-12-23 | Cell co-expressing chimeric antigen receptors binding cd19 and cd22 |
| CA3224507A Pending CA3224507A1 (en) | 2014-12-24 | 2015-12-23 | Cell co-expressing chimeric antigen receptors binding cd19 and cd22 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3224507A Pending CA3224507A1 (en) | 2014-12-24 | 2015-12-23 | Cell co-expressing chimeric antigen receptors binding cd19 and cd22 |
Country Status (26)
| Country | Link |
|---|---|
| US (8) | US11091532B2 (OSRAM) |
| EP (3) | EP4368704A3 (OSRAM) |
| JP (5) | JP6633081B2 (OSRAM) |
| KR (6) | KR102085349B1 (OSRAM) |
| CN (2) | CN107002045B (OSRAM) |
| AU (5) | AU2015370679C1 (OSRAM) |
| BR (1) | BR112017013690A2 (OSRAM) |
| CA (2) | CA2970440A1 (OSRAM) |
| CL (3) | CL2017001314A1 (OSRAM) |
| DK (2) | DK3560953T5 (OSRAM) |
| ES (2) | ES2976197T3 (OSRAM) |
| FI (1) | FI3560953T3 (OSRAM) |
| HR (1) | HRP20240357T1 (OSRAM) |
| HU (2) | HUE066020T2 (OSRAM) |
| IL (4) | IL274903B (OSRAM) |
| LT (1) | LT3560953T (OSRAM) |
| MX (1) | MX2017006233A (OSRAM) |
| PL (2) | PL3560953T3 (OSRAM) |
| PT (2) | PT3560953T (OSRAM) |
| RS (1) | RS65343B1 (OSRAM) |
| RU (2) | RU2768019C2 (OSRAM) |
| SG (2) | SG11201704084VA (OSRAM) |
| SI (1) | SI3560953T1 (OSRAM) |
| SM (1) | SMT202400134T1 (OSRAM) |
| WO (1) | WO2016102965A1 (OSRAM) |
| ZA (1) | ZA201703381B (OSRAM) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| GB201415347D0 (en) * | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| PT3560953T (pt) | 2014-12-24 | 2024-03-26 | Autolus Ltd | Célula |
| PL3253865T3 (pl) | 2015-02-06 | 2022-10-10 | National University Of Singapore | Sposoby wzmacniania skuteczności terapeutycznych komórek odpornościowych |
| SG10201908203SA (en) | 2015-03-05 | 2019-10-30 | Hutchinson Fred Cancer Res | Immunomodulatory Fusion Proteins And Uses Thereof |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| PT3280729T (pt) | 2015-04-08 | 2022-08-01 | Novartis Ag | Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19 |
| GB201507119D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| GB201507115D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| TW202444897A (zh) | 2015-06-25 | 2024-11-16 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| GB201610515D0 (en) * | 2016-06-16 | 2016-08-03 | Autolus Ltd | Cell |
| CA3029197A1 (en) * | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| EP4282969A3 (en) * | 2016-09-02 | 2024-01-31 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
| CN110225927B (zh) | 2016-10-07 | 2024-01-12 | 诺华股份有限公司 | 用于治疗癌症的嵌合抗原受体 |
| JP7778468B2 (ja) | 2016-11-22 | 2025-12-02 | ナショナル ユニバーシティ オブ シンガポール | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
| BR112019011277A2 (pt) | 2016-12-02 | 2019-10-22 | University Of Southern California | polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos. |
| JP2020503015A (ja) * | 2016-12-13 | 2020-01-30 | カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 抗ｃｄ１９のヒト化抗体及びｃｄ１９を標的とする免疫エフェクター細胞 |
| EP3567049A4 (en) * | 2016-12-28 | 2020-08-26 | Green Cross Lab Cell Corporation | CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME |
| US12473343B2 (en) | 2017-01-10 | 2025-11-18 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
| WO2018170475A1 (en) | 2017-03-17 | 2018-09-20 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| JP7505885B2 (ja) | 2017-04-14 | 2024-06-25 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
| US20200048618A1 (en) * | 2017-04-18 | 2020-02-13 | Autolus Limited | Cell |
| CN110753555A (zh) | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| US11980640B2 (en) | 2017-05-15 | 2024-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
| WO2018237022A1 (en) | 2017-06-21 | 2018-12-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| JP2020530993A (ja) * | 2017-08-02 | 2020-11-05 | オートラス リミテッド | キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞 |
| SG11202000402PA (en) | 2017-08-10 | 2020-02-27 | Nat Univ Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| CN109385402A (zh) * | 2017-08-11 | 2019-02-26 | 上海恒润达生生物科技有限公司 | 一种等比例混合两种靶点cart细胞的制备方法及应用 |
| CN107446937B (zh) * | 2017-09-05 | 2020-12-25 | 深圳华云生物技术有限公司 | 嵌合抗原受体及其表达基因、光控调节的嵌合抗原受体修饰的t细胞及其应用 |
| JP7654240B2 (ja) | 2017-09-19 | 2025-04-01 | マサチューセッツ インスティテュート オブ テクノロジー | キメラ抗原受容体ｔ細胞治療のための組成物およびその使用 |
| JP7275118B2 (ja) | 2017-10-16 | 2023-05-17 | レンティジェン・テクノロジー・インコーポレイテッド | 抗ｃｄ２２免疫療法によってがんを処置するための組成物および方法 |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN109988242A (zh) * | 2018-01-02 | 2019-07-09 | 武汉波睿达生物科技有限公司 | 联合嵌合抗原受体、表达载体、慢病毒及t细胞 |
| CN108101994B (zh) * | 2018-01-04 | 2020-09-15 | 广东万海细胞生物科技有限公司 | 抗cd19抗体及其应用 |
| CN120154716A (zh) | 2018-01-22 | 2025-06-17 | 恩多塞特公司 | Car t细胞的使用方法 |
| JP7774961B2 (ja) | 2018-02-06 | 2025-11-25 | シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート | フルオレセイン結合エーテルリン脂質（ｆｌ－ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ |
| JP2021512635A (ja) * | 2018-02-12 | 2021-05-20 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍微小環境を標的とするキメラ抗原受容体 |
| CN110157738B (zh) * | 2018-02-13 | 2023-06-27 | 亘喜生物科技（上海）有限公司 | 靶向cd19和cd22的工程化免疫细胞及其应用 |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| CN112119096B (zh) * | 2018-05-15 | 2024-04-30 | 奥托路斯有限公司 | 嵌合抗原受体 |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| AU2019275076B2 (en) | 2018-05-23 | 2024-12-19 | National University Of Singapore | Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies |
| WO2020011247A1 (en) * | 2018-07-13 | 2020-01-16 | Nanjing Legend Biotech Co., Ltd. | Co-receptor systems for treating infectious diseases |
| MX2021003636A (es) | 2018-09-27 | 2021-07-21 | Autolus Ltd | Receptor antigenico quimerico. |
| SG11202100935TA (en) | 2018-09-28 | 2021-02-25 | Massachusetts Inst Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| GB201816522D0 (en) | 2018-10-10 | 2018-11-28 | Autolus Ltd | Methods and reagents for analysing nucleic acids from single cells |
| GB201820547D0 (en) * | 2018-12-17 | 2019-01-30 | Oxford Univ Innovation | Modified antibodies |
| CN113543792A (zh) * | 2019-03-08 | 2021-10-22 | 奥托路斯有限公司 | 包含工程化嵌合抗原受体和car调节剂的组合物和方法 |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| KR20220010722A (ko) * | 2019-05-16 | 2022-01-26 | 난징 레전드 바이오테크 씨오., 엘티디. | Cd4 결합 모이어티를 포함하는 면역 세포 수용체 |
| AU2020286471B2 (en) * | 2019-06-07 | 2025-07-31 | The Trustees Of The University Of Pennsylvania | Dual CAR expressing T cells individually linked to CD28 and 4-1BB |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| US11642409B2 (en) | 2019-06-26 | 2023-05-09 | Massachusetts Insttute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| US20220257757A1 (en) | 2019-07-16 | 2022-08-18 | Autolus Limited | Method for preconditioning a subject who is about to receive a t-cell therapy |
| GB201910185D0 (en) | 2019-07-16 | 2019-08-28 | Autolus Ltd | Method |
| AU2020325315A1 (en) | 2019-08-07 | 2022-03-24 | Aqualung Therapeutics Corp. | Anti-NAMPT antibodies and uses thereof |
| CN112390891B (zh) * | 2019-08-14 | 2022-06-03 | 苏州方德门达新药开发有限公司 | 嵌合抗原受体及其构建方法和应用 |
| CN110903401A (zh) * | 2019-11-20 | 2020-03-24 | 浙江大学 | 一种靶向cd19的二代嵌合抗原受体及其表达载体与应用 |
| PH12022551291A1 (en) * | 2019-11-26 | 2023-11-20 | Novartis Ag | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
| PH12022551290A1 (en) * | 2019-11-26 | 2023-11-29 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| US20230172981A1 (en) * | 2020-02-04 | 2023-06-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells |
| WO2021180890A1 (en) * | 2020-03-11 | 2021-09-16 | Fundació Institut De Recerca Contra La Leucèmia Josep Carreras | Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all) |
| US12433954B2 (en) | 2020-05-01 | 2025-10-07 | Massachusetts Institute Of Technology | Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs |
| US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| GB202006820D0 (en) | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| JP2023530919A (ja) | 2020-06-17 | 2023-07-20 | ヤンセン バイオテツク，インコーポレーテツド | 多能性幹細胞の製造のための材料及び方法 |
| CN116670154A (zh) | 2020-07-24 | 2023-08-29 | 总医院公司 | 增强的病毒样颗粒及使用其递送至细胞的方法 |
| AU2021333653A1 (en) * | 2020-08-25 | 2023-03-23 | Cytoimmune Therapeutics, Inc. | Bispecific antibody car cell immunotherapy |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| CN112481284B (zh) * | 2020-12-07 | 2023-07-25 | 深圳瑞吉生物科技有限公司 | 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用 |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| KR102393776B1 (ko) | 2020-12-30 | 2022-05-04 | (주)이노베이션바이오 | Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체 |
| US20230174651A1 (en) | 2021-06-23 | 2023-06-08 | Janssen Biotech, Inc. | Materials and methods for hinge regions in functional exogenous receptors |
| WO2023016554A1 (zh) * | 2021-08-13 | 2023-02-16 | 上海医药集团股份有限公司 | 靶向cd22的抗原结合蛋白及其用途 |
| KR102829757B1 (ko) * | 2021-11-17 | 2025-07-09 | (주)이노베이션바이오 | 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체 |
| EP4522204A1 (en) | 2022-05-11 | 2025-03-19 | Autolus Limited | Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia |
| EP4558151A1 (en) | 2022-07-22 | 2025-05-28 | Janssen Biotech, Inc. | Enhanced transfer of genetic instructions to effector immune cells |
| US20240197780A1 (en) * | 2022-12-19 | 2024-06-20 | Development Center For Biotechnology | Chimeric antigen receptors, nucleic acids encoding the same, and uses thereof in treating cancers |
| WO2024196796A1 (en) * | 2023-03-17 | 2024-09-26 | Cartesian Therapeutics, Inc. | Intracellular signaling and costimulatory domains adapted for prolonged expression of chimeric antigen receptors |
| CN121219004A (zh) | 2023-05-30 | 2025-12-26 | 奥托路斯有限公司 | 复发性/难治性b细胞急性成淋巴细胞性白血病的cd19car t细胞治疗 |
| WO2024250037A1 (en) * | 2023-06-02 | 2024-12-05 | Northeastern University | Targeted immune cell therapy utilizing trail and tnf mediated apoptosis |
| WO2025088308A1 (en) | 2023-10-23 | 2025-05-01 | Autolus Limited | Products and methods for treating autoimmune diseases |
| GB202403564D0 (en) | 2024-03-12 | 2024-04-24 | Autolus Ltd | Method |
| WO2025215360A1 (en) | 2024-04-09 | 2025-10-16 | Autolus Limited | Method |
| WO2025231185A1 (en) | 2024-05-01 | 2025-11-06 | Legend Biotech Ireland Limited | Viral glycoprotein variants and uses thereof |
| NL2037811B1 (en) | 2024-05-29 | 2025-12-12 | Univ Oslo | Treatment for Cancer |
| WO2025259108A1 (en) | 2024-06-11 | 2025-12-18 | Prinses Máxima Centrum Voor Kinderoncologie B.V. | Brain organoid |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2299011A1 (fr) | 1975-01-29 | 1976-08-27 | Obert Jean Claude | Generateur d'aerosols de part |
| GB9908807D0 (en) | 1999-04-16 | 1999-06-09 | Celltech Therapeutics Ltd | Synthetic signalling molecules |
| US7052906B1 (en) | 1999-04-16 | 2006-05-30 | Celltech R & D Limited | Synthetic transmembrane components |
| JP5312721B2 (ja) * | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Ｃｄ１９特異的再指向免疫細胞 |
| WO2004106381A1 (en) * | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| PT1976886E (pt) | 2005-12-16 | 2015-03-09 | Amgen Res Munich Gmbh | Meios e processos para o tratamento de doenças tumorais |
| WO2010085660A2 (en) * | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| BR112014008849A2 (pt) * | 2011-10-20 | 2017-09-12 | Us Health | receptores quiméricos de antígeno anti-cd22 |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| CN103483452B (zh) | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| CA2876730A1 (en) | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
| KR102198058B1 (ko) * | 2012-10-02 | 2021-01-06 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2013335180B2 (en) | 2012-10-24 | 2018-07-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | M971 chimeric antigen receptors |
| KR102417657B1 (ko) * | 2013-02-06 | 2022-07-07 | 안트로제네시스 코포레이션 | 개선된 특이성을 갖는 변경된 t 림프구 |
| WO2014138704A1 (en) | 2013-03-07 | 2014-09-12 | Baylor College Of Medicine | Targeting cd138 in cancer |
| ES2769574T3 (es) | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| CA2904265C (en) | 2013-03-15 | 2023-08-08 | Victor D. FEDOROV | Compositions and methods for immunotherapy |
| RU2727447C2 (ru) | 2013-05-13 | 2020-07-21 | Селлектис | Cd19-специфический химерный антигенный рецептор и его применения |
| WO2015010096A1 (en) | 2013-07-18 | 2015-01-22 | Baylor College Of Medicine | Method of enhancing potency of immune cells |
| EP3071222B1 (en) * | 2013-11-21 | 2020-10-21 | UCL Business Ltd | Cell |
| JP2017504601A (ja) | 2013-12-20 | 2017-02-09 | セレクティスＣｅｌｌｅｃｔｉｓ | 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法 |
| PT3560953T (pt) | 2014-12-24 | 2024-03-26 | Autolus Ltd | Célula |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| GB201507111D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
| TW202444897A (zh) | 2015-06-25 | 2024-11-16 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| GB201518816D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| GB201610515D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Cell |
| CN112119096B (zh) | 2018-05-15 | 2024-04-30 | 奥托路斯有限公司 | 嵌合抗原受体 |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
-
2015
- 2015-12-23 PT PT191723972T patent/PT3560953T/pt unknown
- 2015-12-23 PL PL19172397.2T patent/PL3560953T3/pl unknown
- 2015-12-23 IL IL274903A patent/IL274903B/en unknown
- 2015-12-23 FI FIEP19172397.2T patent/FI3560953T3/fi active
- 2015-12-23 IL IL292508A patent/IL292508B2/en unknown
- 2015-12-23 PL PL15817520T patent/PL3237442T3/pl unknown
- 2015-12-23 BR BR112017013690-2A patent/BR112017013690A2/pt not_active Application Discontinuation
- 2015-12-23 HU HUE19172397A patent/HUE066020T2/hu unknown
- 2015-12-23 RS RS20240357A patent/RS65343B1/sr unknown
- 2015-12-23 HR HRP20240357TT patent/HRP20240357T1/hr unknown
- 2015-12-23 HU HUE15817520A patent/HUE046262T2/hu unknown
- 2015-12-23 ES ES19172397T patent/ES2976197T3/es active Active
- 2015-12-23 SG SG11201704084VA patent/SG11201704084VA/en unknown
- 2015-12-23 RU RU2017121892A patent/RU2768019C2/ru active
- 2015-12-23 MX MX2017006233A patent/MX2017006233A/es active IP Right Grant
- 2015-12-23 KR KR1020177019393A patent/KR102085349B1/ko active Active
- 2015-12-23 LT LTEP19172397.2T patent/LT3560953T/lt unknown
- 2015-12-23 SI SI201531999T patent/SI3560953T1/sl unknown
- 2015-12-23 PT PT15817520T patent/PT3237442T/pt unknown
- 2015-12-23 CN CN201580065695.4A patent/CN107002045B/zh active Active
- 2015-12-23 KR KR1020227031979A patent/KR20220129684A/ko not_active Ceased
- 2015-12-23 RU RU2022102250A patent/RU2022102250A/ru unknown
- 2015-12-23 KR KR1020197038792A patent/KR20200003939A/ko not_active Ceased
- 2015-12-23 SM SM20240134T patent/SMT202400134T1/it unknown
- 2015-12-23 KR KR1020217024459A patent/KR102376244B1/ko active Active
- 2015-12-23 JP JP2017533969A patent/JP6633081B2/ja active Active
- 2015-12-23 US US15/529,690 patent/US11091532B2/en active Active
- 2015-12-23 DK DK19172397.2T patent/DK3560953T5/da active
- 2015-12-23 CA CA2970440A patent/CA2970440A1/en active Pending
- 2015-12-23 EP EP23217769.1A patent/EP4368704A3/en active Pending
- 2015-12-23 CA CA3224507A patent/CA3224507A1/en active Pending
- 2015-12-23 DK DK15817520.8T patent/DK3237442T3/da active
- 2015-12-23 SG SG10202111107RA patent/SG10202111107RA/en unknown
- 2015-12-23 KR KR1020237036909A patent/KR20230152824A/ko active Pending
- 2015-12-23 KR KR1020217024458A patent/KR102376242B1/ko active Active
- 2015-12-23 ES ES15817520T patent/ES2744910T3/es active Active
- 2015-12-23 AU AU2015370679A patent/AU2015370679C1/en active Active
- 2015-12-23 IL IL301458A patent/IL301458A/en unknown
- 2015-12-23 EP EP15817520.8A patent/EP3237442B1/en not_active Revoked
- 2015-12-23 CN CN202111208410.1A patent/CN114107212A/zh active Pending
- 2015-12-23 EP EP19172397.2A patent/EP3560953B1/en active Active
- 2015-12-23 WO PCT/GB2015/054137 patent/WO2016102965A1/en not_active Ceased
-
2017
- 2017-05-10 IL IL252208A patent/IL252208B/en unknown
- 2017-05-16 ZA ZA2017/03381A patent/ZA201703381B/en unknown
- 2017-05-23 CL CL2017001314A patent/CL2017001314A1/es unknown
- 2017-06-23 US US15/631,948 patent/US10098926B2/en active Active
- 2017-06-23 US US15/632,119 patent/US10174099B2/en active Active
-
2018
- 2018-06-29 US US16/024,445 patent/US10981970B2/en active Active
- 2018-11-13 CL CL2018003216A patent/CL2018003216A1/es unknown
- 2018-11-13 CL CL2018003217A patent/CL2018003217A1/es unknown
- 2018-12-06 US US16/211,538 patent/US11034750B2/en active Active
-
2019
- 2019-11-14 JP JP2019206023A patent/JP6909844B2/ja active Active
-
2020
- 2020-02-07 US US16/785,467 patent/US20200181232A1/en not_active Abandoned
- 2020-08-06 AU AU2020213352A patent/AU2020213352B2/en active Active
- 2020-12-01 JP JP2020199333A patent/JP7514746B2/ja active Active
-
2021
- 2021-10-19 JP JP2021170769A patent/JP2022002546A/ja not_active Withdrawn
-
2022
- 2022-07-12 AU AU2022205169A patent/AU2022205169B2/en active Active
- 2022-07-12 AU AU2022205170A patent/AU2022205170B2/en active Active
-
2023
- 2023-01-24 US US18/158,754 patent/US12398194B2/en active Active
-
2024
- 2024-03-05 JP JP2024032851A patent/JP2024055976A/ja active Pending
- 2024-12-10 AU AU2024278248A patent/AU2024278248A1/en active Pending
-
2025
- 2025-07-25 US US19/281,399 patent/US20250353893A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12398194B2 (en) | Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface | |
| CN112119096B (zh) | 嵌合抗原受体 | |
| KR20230095083A (ko) | Cd7 표적의 키메라 항원 수용체 및 이의 용도 | |
| IL297901A (en) | cell | |
| HK1243425A1 (en) | Cell | |
| HK1243425B (en) | Cell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201103 |
|
| EEER | Examination request |
Effective date: 20201103 |
|
| EEER | Examination request |
Effective date: 20201103 |
|
| EEER | Examination request |
Effective date: 20201103 |
|
| EEER | Examination request |
Effective date: 20201103 |
|
| EEER | Examination request |
Effective date: 20201103 |
|
| EEER | Examination request |
Effective date: 20201103 |